LifeStance Health Group (NASDAQ:LFST) Price Target Raised to $13.00 at JPMorgan Chase & Co.

LifeStance Health Group (NASDAQ:LFST) had its price target upped by investment analysts at JPMorgan Chase & Co. from $9.00 to $13.00 in a research note issued to investors on Friday,Benzinga reports. The brokerage currently has a “neutral” rating on the stock. JPMorgan Chase & Co.‘s target price would suggest a potential upside of 2.48% from the stock’s current price.

Several other equities research analysts also recently commented on LFST. The Goldman Sachs Group initiated coverage on LifeStance Health Group in a report on Friday, June 5th. They set a “neutral” rating and a $9.00 target price on the stock. BTIG Research increased their price objective on shares of LifeStance Health Group from $15.00 to $16.00 and gave the company a “buy” rating in a research report on Friday, August 7th. Barclays lifted their price objective on shares of LifeStance Health Group from $9.00 to $13.00 and gave the company an “overweight” rating in a research note on Tuesday, July 14th. Wall Street Zen cut shares of LifeStance Health Group from a “strong-buy” rating to a “buy” rating in a research report on Saturday, July 25th. Finally, KeyCorp upped their target price on shares of LifeStance Health Group from $11.00 to $13.00 and gave the company an “overweight” rating in a research note on Monday, July 13th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $12.12.

LifeStance Health Group Stock Up 3.8%

LifeStance Health Group stock traded up $0.47 during trading on Friday, reaching $12.69. 2,264,981 shares of the company’s stock were exchanged, compared to its average volume of 3,440,173. LifeStance Health Group has a 52-week low of $4.77 and a 52-week high of $12.72. The firm has a market cap of $4.92 billion, a price-to-earnings ratio of 97.73 and a beta of 1.14. The company has a debt-to-equity ratio of 0.18, a quick ratio of 1.38 and a current ratio of 1.38. The company’s 50-day moving average is $10.29 and its two-hundred day moving average is $8.19.

LifeStance Health Group (NASDAQ:LFST) last released its quarterly earnings data on Thursday, August 6th. The company reported $0.06 EPS for the quarter, beating the consensus estimate of $0.03 by $0.03. The company had revenue of $435.35 million for the quarter, compared to analyst estimates of $414.58 million. LifeStance Health Group had a return on equity of 3.39% and a net margin of 3.19%.The firm’s revenue was up 26.1% compared to the same quarter last year. During the same period last year, the company posted ($0.01) earnings per share. On average, analysts predict that LifeStance Health Group will post 0.15 earnings per share for the current year.

Insiders Place Their Bets

In related news, Director Robert Bessler sold 894,337 shares of the company’s stock in a transaction on Friday, June 26th. The shares were sold at an average price of $10.13, for a total value of $9,059,633.81. Following the sale, the director directly owned 539,763 shares of the company’s stock, valued at $5,467,799.19. This represents a 62.36% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CTO Vukasin Paunovich sold 44,394 shares of the stock in a transaction on Monday, August 10th. The shares were sold at an average price of $10.85, for a total transaction of $481,674.90. Following the transaction, the chief technology officer owned 247,446 shares in the company, valued at $2,684,789.10. This trade represents a 15.21% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 14,629,850 shares of company stock valued at $154,952,012. Corporate insiders own 3.50% of the company’s stock.

Institutional Investors Weigh In On LifeStance Health Group

Hedge funds and other institutional investors have recently modified their holdings of the stock. Royal Bank of Canada raised its stake in shares of LifeStance Health Group by 63.4% in the 1st quarter. Royal Bank of Canada now owns 70,248 shares of the company’s stock valued at $468,000 after purchasing an additional 27,244 shares in the last quarter. AQR Capital Management LLC grew its stake in LifeStance Health Group by 223.0% in the first quarter. AQR Capital Management LLC now owns 51,500 shares of the company’s stock worth $343,000 after purchasing an additional 35,554 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in LifeStance Health Group by 3.0% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 142,950 shares of the company’s stock worth $952,000 after purchasing an additional 4,169 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in LifeStance Health Group by 1.9% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 615,652 shares of the company’s stock valued at $4,100,000 after buying an additional 11,331 shares during the last quarter. Finally, JPMorgan Chase & Co. increased its holdings in LifeStance Health Group by 10.2% in the second quarter. JPMorgan Chase & Co. now owns 550,657 shares of the company’s stock valued at $2,847,000 after buying an additional 51,154 shares during the last quarter. Institutional investors own 85.50% of the company’s stock.

About LifeStance Health Group

LifeStance Health Group (NASDAQ:LFST) is a leading provider of outpatient mental health services in the United States. Headquartered in New York City, the company operates a growing network of clinics that deliver integrated, patient-centered psychological and psychiatric care. LifeStance’s mission is to expand access to high-quality mental health treatment by combining evidence-based therapy modalities with personalized treatment plans.

The company’s service offerings include individual, family, and group psychotherapy, psychiatric medication management, psychological assessment, and telehealth services.